Nuclear / MolecularBody / AbdominalNewsBrief

FDA Clears U.S. Expansion of Telix's Phase 3 ProstACT Trial

Applied Radiologyvia Google NewsJul 9

FDA clears path for U.S. expansion of Telix's Phase 3 ProstACT trial in metastatic prostate cancer.

Read the source

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.